Title: LIFE studies in hypertensive pts in reducing various cv morbidities & mortalities including stroke
Article Number: EC/2014/116
Authors: Manan K Trivedi
Topic: Clinical Research
Main objective of the
article is to critically assess and analyze beneficial effects of losartan Vs.
atenolol along with its safety and efficacy profile in different composite
endpoints of CV morbidities and mortalities like MI, stroke, ISH, AF and new
onset of diabetes and in comparison to atenolol group in hypertensive patients.
Also to assess such beneficial effects in combination therapy of losartan and
aspirin on the same outcomes.
clinical trials and review articles were identified through a MEDLINE search of
English-language articles published between 1990 and 2013 using the search
terms losartan, atenolol, LIFE, hypertension, and LVH. Articles describing
major clinical studies, new data, or mechanisms pertinent to the LIFE study
were selected for review. Total of 7 such clinical studies are reviewed and
analyzed for its results.
The LIFE-study included
9193 patients with essential hypertension and ECG-verified left ventricular
hypertrophy, age range 55-80 years. Patients were randomized to double-blind
treatment with losartan vs. atenolol. They were followed for at least four
years and until 1040 patients had a primary cardiovascular event.
Losartan attained 33%
reduction in new onset of AF with subsequent stroke vs. atenolol. Results of
these studies shows there were 45% reduced rate of stroke events. There was no
difference in MI. New onset of diabetes
was 25% less frequent on losartan. Side effects were less on losartan vs. atenolol
LIFE studies justified
efficacy and safety profile of losartan against atenolol in not only stroke but
also other cardiovascular morbidities and mortalities with similar composite
endpoint reduction in combination therapy of losartan with aspirin.
KEYWORDS: LIFE (Losartan Intervention For Endpoint reduction in hypertension), ISH (isolated systolic hypertension), MI (Myocardial Infarction), AF (Atrial fibrillation), LVH (Left Ventricular Hypertrophy), CV (Cardiovascular)
You can post and view your comments and reply in full.
Access and participate actively in the open forum, and make your Research visible
Please follow the following steps to participate in Open Forum